QNCX Logo

Quince Therapeutics, Inc. (QNCX) Stock Forecast & Price Prediction

Live QNCX Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$1.67

+0.12 (7.74%)

12 Month Price Forecast For QNCX

$1.67
Current Price
$73.48M
Market Cap
3 Ratings
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to QNCX Price Forecasts

+618.6%
To High Target of $12.00
+438.9%
To Median Target of $9.00
+259.3%
To Low Target of $6.00

QNCX Price Momentum

+4.4%
1 Week Change
-16.1%
1 Month Change
+29.5%
1 Year Change
-10.7%
Year-to-Date Change
-31.8%
From 52W High of $2.45
+226.2%
From 52W Low of $0.51

๐Ÿค” Considering Quince Therapeutics (QNCX)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 6, 2025 6:09 AM UTC

QNCX Analyst Ratings & Price Targets

Based on our analysis of 4 Wall Street analysts, QNCX has a consensus that is bullish. The median price target is $9.00, with forecasts ranging from $6.00 to $12.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With QNCX currently trading at $1.67, the median price forecast suggests a 438.9% upside. The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 618.6% upside, while Jason McCarthy at Maxim Group provides the most conservative target, suggesting a 259.3% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

QNCX Analyst Consensus

3
Buy
0
Hold
0
Sell

QNCX Price Target Range

Low
$6.00
Average
$9.00
High
$12.00
Current: $1.67

Latest QNCX Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for QNCX.

Date Firm Analyst Rating Change Price Target
Feb 5, 2025 D. Boral Capital Jason Kolbert Buy Maintains $12.00
Jan 2, 2025 D. Boral Capital Jason Kolbert Buy Maintains $12.00
Dec 18, 2024 Brookline Capital Buy Initiates $0.00
Nov 14, 2024 D. Boral Capital Jason Kolbert Buy Maintains $12.00
Nov 12, 2024 D. Boral Capital Jason Kolbert Buy Maintains $12.00
Nov 7, 2024 Maxim Group Jason McCarthy Buy Initiates $6.00
Oct 29, 2024 Rodman & Renshaw Elemer Piros Buy Initiates $11.00
Oct 22, 2024 EF Hutton Jason Kolbert Buy Initiates $12.00
May 11, 2022 Credit Suisse Underperform Maintains $0.00
Mar 9, 2022 HC Wainwright & Co. Buy Maintains $0.00
Jan 28, 2022 Canaccord Genuity Hold Downgrade $0.00
Jan 27, 2022 JMP Securities Market Perform Downgrade $0.00
Oct 27, 2021 B of A Securities Underperform Downgrade $0.00
Oct 27, 2021 HC Wainwright & Co. Buy Maintains $0.00
Sep 16, 2021 Canaccord Genuity Buy Maintains $0.00
Aug 26, 2021 HC Wainwright & Co. Buy Maintains $0.00
Feb 17, 2021 Jefferies Hold Downgrade $0.00
Dec 11, 2020 Citigroup Sell Initiates $0.00
Dec 7, 2020 B of A Securities Buy Upgrade $0.00
Jun 24, 2020 HC Wainwright & Co. Buy Initiates $0.00

Stocks Similar to Quince Therapeutics, Inc.

The following stocks are similar to Quince Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Quince Therapeutics, Inc. (QNCX) Financial Data

Quince Therapeutics, Inc. has a market capitalization of $73.48M with a P/E ratio of -2.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -79.4%.

Valuation Metrics

Market Cap $73.48M
Enterprise Value $37.16M
P/E Ratio -2.0x
PEG Ratio -5.4x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +82.3%
Current Ratio 6.1x
Debt/Equity 30.6x
ROE -79.4%
ROA -16.5%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Quince Therapeutics, Inc. logo

Quince Therapeutics, Inc. (QNCX) Company Overview

About Quince Therapeutics, Inc.

What They Do

Develops therapeutics for rare diseases.

Business Model

Quince Therapeutics operates as a biopharmaceutical company focused on acquiring and commercializing innovative therapeutics for rare and debilitating diseases. The company generates revenue through the development and potential commercialization of its lead asset, EryDex, which targets rare pediatric neurodegenerative disorders. Additionally, their AIDE technology platform offers a unique drug/device combination that enhances treatment efficacy, potentially leading to lucrative market opportunities.

Additional Information

Founded in 2012 and headquartered in South San Francisco, California, Quince Therapeutics was previously known as Cortexyme, Inc. The company's focus on rare diseases aligns with increasing investor interest in specialized therapeutics, which may provide a competitive edge in a niche market.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

32

CEO

Dr. Dirk Thye M.D.

Country

United States

IPO Year

2019

Quince Therapeutics, Inc. (QNCX) Latest News & Analysis

QNCX stock latest news image
Quick Summary

Quince Therapeutics (Nasdaq: QNCX) published safety data for EryDex, used in treating Ataxia-Telangiectasia, in Frontiers in Neurology, highlighting its potential for addressing unmet medical needs.

Why It Matters

Safety data publication for EryDex in treating Ataxia-Telangiectasia could signal progress for Quince Therapeutics, potentially increasing investor confidence and stock value.

Source: Business Wire
Market Sentiment: Neutral
QNCX stock latest news image
Quick Summary

Quince Therapeutics (Nasdaq: QNCX) will host an investor webinar on February 7, 2025, to discuss its treatment for the rare pediatric disease Ataxia-Telangiectasia.

Why It Matters

Quince Therapeutics' webinar highlights its focus on a rare disease, potentially attracting investor interest in its innovative treatments and future growth prospects.

Source: Business Wire
Market Sentiment: Neutral
QNCX stock latest news image
Quick Summary

Quince Therapeutics (Nasdaq: QNCX) appointed Dr. William Whitehouse as a new board member. He is an Honorary Clinical Associate Professor and former Consultant Paediatric Neurologist.

Why It Matters

The appointment of Dr. Whitehouse enhances Quince Therapeutics' credibility and expertise in rare disease treatment, potentially boosting investor confidence and stock performance.

Source: Business Wire
Market Sentiment: Neutral
QNCX stock latest news image
Quick Summary

Quince Therapeutics (Nasdaq: QNCX) reported Q3 2024 financial results and updates on its development pipeline, noting accelerating enrollment in clinical trials.

Why It Matters

Quince Therapeutics' pipeline update and financial results signal progress in rare disease treatments, potentially enhancing investor confidence and impacting stock performance.

Source: Business Wire
Market Sentiment: Neutral
QNCX stock latest news image
Quick Summary

Quince Therapeutics (Nasdaq: QNCX) presented safety data from its Phase 3 ATTeST trial at the CNS Annual Meeting, focusing on treatments for rare diseases.

Why It Matters

Quince Therapeutics' presentation of safety data from its Phase 3 trial could influence investor confidence and stock performance, signaling progress in addressing rare diseases.

Source: Business Wire
Market Sentiment: Neutral
QNCX stock latest news image
Quick Summary

Quince Therapeutics (Nasdaq: QNCX) presented data from its Phase 3 ATTeST trial for EryDex at the 2024 International Congress for Ataxia Research, focusing on treatments for rare diseases.

Why It Matters

Quince Therapeutics' presentation at a major conference highlights progress in their Phase 3 clinical trial, potentially boosting investor confidence in their lead asset and future growth.

Source: Business Wire
Market Sentiment: Neutral

Frequently Asked Questions About QNCX Stock

What is Quince Therapeutics, Inc.'s (QNCX) stock forecast for 2025?

Based on our analysis of 4 Wall Street analysts, Quince Therapeutics, Inc. (QNCX) has a median price target of $9.00. The highest price target is $12.00 and the lowest is $6.00.

Is QNCX stock a good investment in 2025?

According to current analyst ratings, QNCX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.67. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for QNCX stock?

Wall Street analysts predict QNCX stock could reach $9.00 in the next 12 months. This represents a 438.9% increase from the current price of $1.67. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Quince Therapeutics, Inc.'s business model?

Quince Therapeutics operates as a biopharmaceutical company focused on acquiring and commercializing innovative therapeutics for rare and debilitating diseases. The company generates revenue through the development and potential commercialization of its lead asset, EryDex, which targets rare pediatric neurodegenerative disorders. Additionally, their AIDE technology platform offers a unique drug/device combination that enhances treatment efficacy, potentially leading to lucrative market opportunities.

What is the highest forecasted price for QNCX Quince Therapeutics, Inc.?

The highest price target for QNCX is $12.00 from Jason Kolbert at D. Boral Capital, which represents a 618.6% increase from the current price of $1.67.

What is the lowest forecasted price for QNCX Quince Therapeutics, Inc.?

The lowest price target for QNCX is $6.00 from Jason McCarthy at Maxim Group, which represents a 259.3% increase from the current price of $1.67.

What is the overall QNCX consensus from analysts for Quince Therapeutics, Inc.?

The overall analyst consensus for QNCX is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.

How accurate are QNCX stock price projections?

Stock price projections, including those for Quince Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.